Hoffmann-La Roche
erlotinib(Hoffmann-La Roche)은 Advanced Solid Tumors 표적 치료제로, Hepatocellular Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targeting epidermal growth factor receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 72% (ClinicalTrials.gov NCT01130519). PK: t½ 36.2 h. 차별점: Novel PHGDH Inhibitors for Overcoming Erlotinib-Resistant Lung Cancer.
Advanced Solid Tumors
Hepatocellular Carcinoma
Active
CAR-T cells, and bispecific antibodies, as well as targeted deliv
SN-38, indicated by higher IC 20 and IC 20 /3
Novel PHGDH Inhibitors for Overcoming Erlotinib-Resistant Lung Cancer
targeting epidermal growth factor receptor
apoptosis in treated cells, suggests a possible secondary anticancer mechanism
EGFR expression
resistance mechanisms in more aggressive cancers and can thus be pursued further in preclinical optimization
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Hoffmann-La Roche
erlotinib(Hoffmann-La Roche)은 Advanced Solid Tumors 표적 치료제로, Hepatocellular Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targeting epidermal growth factor receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 72% (ClinicalTrials.gov NCT01130519). PK: t½ 36.2 h. 차별점: Novel PHGDH Inhibitors for Overcoming Erlotinib-Resistant Lung Cancer.
Advanced Solid Tumors
Hepatocellular Carcinoma
Active
CAR-T cells, and bispecific antibodies, as well as targeted deliv
SN-38, indicated by higher IC 20 and IC 20 /3
Novel PHGDH Inhibitors for Overcoming Erlotinib-Resistant Lung Cancer
targeting epidermal growth factor receptor
apoptosis in treated cells, suggests a possible secondary anticancer mechanism
EGFR expression
resistance mechanisms in more aggressive cancers and can thus be pursued further in preclinical optimization
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.